Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells

Fig. 5

AKT1 is a downstream target of SRPK1 inhibitors in YT cells. A YT cells were transfected with SRPK1 siRNA or treated with SPHINX31 (12.5 μM) or SRPIN340 (12.5 μM) for 24 h. Heatmap showed that SRPK1 knockdown and inhibition resulted in similar gene expression patterns, among which AKT1 was downregulated by SRPK1 silencing and inhibition. B The levels of total and phosphorylated AKT1 were downregulated by SRPK1 silencing and inhibition. C Silencing ATF4 by siRNA transfection decreased the expression of ATF4 in YT cells. AKT1 protein levels in YT cells were upregulated by the overexpression plasmid pLVX-SAKT1. D Annexin V/7-AAD double staining showed the effect of AKT1 overexpression on SPHINX31-induced apoptosis in YT cells.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us